Health insurers' top plans for 2018
Payers’ biggest concerns for 2018, health insurance exchange participation plans, and how offerings could change.
Read More
Why dialing back diabetes treatment is a good idea
A new study has unbelievable findings about treating Medicare patients with diabetes.
Healthcare spending is slowing: Here’s why
A Robert Wood Johnson Foundation expert analyzes the Altarum Institute’s study on healthcare growth findings.
Genetic testing in oncology: 5 things payers should know
As genomics continues to evolve, here are five things to know about genetic testing and counseling.
Five ways healthcare executives can better support physicians
A survey explores how physicians perceive their role in the healthcare system, and the findings aren’t good.
Consumers’ top 4 concerns about their physicians
A Physicians Foundation survey gives healthcare executives behind the scenes insight into the physician-patient relationship.
Payers struggle to keep up with high rate of FDA drug approvals
FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.
Four ways health execs can prep for costly CAR-T cell therapies
With the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.
Game-changing gene therapies present cost problems for health execs
CAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.
Payers can predict budget implications of high-cost drugs in the pipeline
A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.
Meeting the ‘status quo’ with CMS Star Ratings equals regression
CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.
Payers need access to pre-approval drug information
Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?
Survey: How payers use nonpayer generated data to make formulary decisions
External, non-payer generated data can inform formulary decision-making-if payers know their strengths and weaknesses.
Study: Formularies may be key to alleviating opioid epidemic
New Yale University research offers stunning findings about drug formulary coverage and prescribing opioids.
Five ways to increase physician engagement
One expert says incentive programs to motivate physicians miss the mark. Here’s what he recommends instead.
Top strategy plans, providers can use to motivate member behavior changes
As the healthcare system shifts from a focus on employee-based plans to consumer-based plans, insurers have to find new ways to engage and motivate members.
Program uses provider, patient incentives to fight opioid epidemic
Providers are coming up short when it comes to HEDIS measures related to substance abuse. Here’s how one health plan is changing that.
Specialty drug pipeline predictions: Seven key areas to watch
The specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.
Monetary benefits from value-based diabetes plans take time
Value-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.
Highly specific indications dominate cancer drug pipeline
Recent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.
Medicare Advantage vs. specialized Medicare Advantage plans: Outcome effects
Avalere Health analysis has intriguing results about beneficiaries enrolled in diabetes-focused chronic condition special needs plans.
Drug shortages likely after hurricanes
FDA Commissioner Scott Gottlieb, MD, said that the United States is likely to see shortages on certain drugs because after Hurricanes Irma and Maria knocked out power to the islands.
Many hospitals not sharing e-patient data
Why researchers say the industry is “a long way off” from robust electronic patient data sharing.
Trump’s steps to undo the ACA: Top takeaways from healthcare insiders
Trump takes two steps to dissolve the ACA. Find out what the experts think about these two important actions.
Five ways Trump’s efforts to strip the ACA will affect healthcare
Here’s a quick guide to the meaning behind Trump’s executive order and decision to stop cost-sharing reduction payments.
Five key focus areas for building a consumer-centric healthcare organization
Here’s how to take consumer-centricity more seriously as expectations increase.
FDA challenges abuse-deterrent opioid drug claim
The FDA pushes back on new painkiller’s abuse-deterrent claims. Here’s why this is important to the opioid epidemic.
Opinion: Four reasons Texas Health Aetna joint venture is working
As the industry moves to a value-based care model, here’s how one North Texas partnership is reinventing healthcare.
This is why you should be excited for upcoming cancer research
Acute myeloid leukemia experts share promising new developments on the oncology horizon.
Study: Patients combine toxic medications with ‘alarming frequency’
A new study uses population health analytics to identify potential opioid abuse, and the study findings are troubling.
